Join our daily newsletter At The Bell to receive exclusive market insights
The 177Lu-RAD202 drug used in conjunction with a similar imaging agent has seen some patients with breast cancer undergo a reduction in tumour size, Radiopharm (ASX:RAD) has reported today after testing.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The microcap’s also launching a first-time human trial – or an “open-label dose escalation Phase 1 study of 177Lu-RAD202” – which is now recruiting in Australia.
Another imaging agent, 68Ga-RAD202, assists with locating tumours in the body while undergoing a PET scan but also treating the cancer. The drugs ‘sniff out’ HER2, a protein the body naturally produces but for which levels shoot up in some cases of breast cancer.
Researchers did note the imaging agent does have higher uptake in the bladder and kidneys even when those are not the target organs. This was “expected.”
“Treatment with 177Lu-RAD202 results in a relevant tumor volume reduction and survival benefit, further pronounced with fractionated therapy vs single-dose treatment,” the company followed.
The upcoming human trial will ultimately seek to establish safety data of using the two products rather than necessarily studying the impacts on cancer cells.
More market news
Together: The U.S. has suspended aid to Ukraine. Will Europe step into the breach?
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
“These data support the potential for RAD202 to address an unmet need for HER2-positive metastatic patients that are progressing on current standard of care, or unable to tolerate current treatment options,” RAD CEO Riccardo Canevari said.
RAD last traded at 2.8cps.
Join the discussion: See what HotCopper users are saying about Radiopharm and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
